Company News from March 15, 2022

  • Ballard Power Systems Inc.’s BLDP shares fell 7.9% after the company reported an adjusted loss per share of $0.15 in the fourth quarter of fiscal 2021, worse than the Zacks consensus estimate a loss per share of $0.08.
  • GOL shares of Gol Linhas Aéreas Inteligentes SA fell 3.1% after the company posted an adjusted loss per share of $0.62 in the fourth quarter of fiscal 2021, above the Zacks consensus estimate a loss per share of $0.41.
  • Shares of Verve Therapeutics Inc. VERV plunged 9.5% after reporting an adjusted loss per share of $0.65 in the fourth quarter of fiscal 2021, above the Zacks consensus estimate of a loss per share of $0.54.
  • Shares of Pfizer Inc. PFE jumped 3.9% after its CEO said the company would likely gain regulatory approval for its COVID-19 vaccine for children under five in May.

Zacks names ‘only one best choice for doubling up’

From thousands of stocks, 5 Zacks experts have each picked their favorite to skyrocket by +100% or more in the coming months. Of these 5, Research Director Sheraz Mian selects one to have the most explosive advantage of all.

It’s a little-known chemical company that’s up 65% year-on-year, but still very cheap. With relentless demand, rising earnings estimates for 2022 and $1.5 billion for stock buybacks, retail investors could jump in at any moment.

This company could rival or surpass other recent Zacks stocks which are expected to double, such as Boston Beer Company which jumped +143.0% in just over 9 months and NVIDIA which jumped +175.9% in one. year.

Free: See our best stock and our 4 finalists >>

Click to get this free report

Pfizer Inc. (PFE): Free Inventory Analysis Report

Gol Linhas Aereas Inteligentes SA (GOL): Free Stock Analysis Report

Ballard Power Systems, Inc. (BLDP): Free Inventory Analysis Report

Verve Therapeutics, Inc. (VERV): Free Stock Analysis Report

To read this article on Zacks.com, click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Karen J. Nelson